Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

4SC Receives Patent on Rheumatoid Arthritis Candidate

  • 4SC was granted a patent related to its rheumatoid arthritis drug candidate, SC12267. The patent protects the DHODH inhibitor. SC 12267 is currently in Phase IIa trials.

    In addition, the patent also covers further back-up substances related to SC12267, medical formulations, and the treatment of patients with SC12267. The patent will apply until 2020.

    This expansion on 4SC’s patent portfolio, explains Ulrich Dauer, CEO, creates “the ideal conditions for a potential licensing partnership within the scope of this project."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »